Cargando…
Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults
OBJECTIVES: The Canadian National Advisory Committee on Immunization (NACI) recommends use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in a sequential schedule (PCV13 → PPV23) among adults aged ≥ 65 years and those aged ≥ 18 years who are immunocompr...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267650/ https://www.ncbi.nlm.nih.gov/pubmed/29981104 http://dx.doi.org/10.17269/s41997-018-0050-9 |
_version_ | 1783376123666628608 |
---|---|
author | Atwood, Mark Beausoleil, Linda Breton, Marie-Claude Laferriere, Craig Sato, Reiko Weycker, Derek |
author_facet | Atwood, Mark Beausoleil, Linda Breton, Marie-Claude Laferriere, Craig Sato, Reiko Weycker, Derek |
author_sort | Atwood, Mark |
collection | PubMed |
description | OBJECTIVES: The Canadian National Advisory Committee on Immunization (NACI) recommends use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in a sequential schedule (PCV13 → PPV23) among adults aged ≥ 65 years and those aged ≥ 18 years who are immunocompromised. In light of recent PCV13 efficacy data from the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA), and new sero-epidemiology data on community-acquired pneumonia (CAP), we examined the economic implications of funding an expanded adult pneumococcal immunization program in Canada. METHODS: A microsimulation model depicting expected lifetime risks, consequences, and costs of invasive pneumococcal disease (IPD) and CAP was developed. PPV23 effectiveness was based on published literature, and PCV13 effectiveness was based on CAPiTA; all other model parameters were based on published data or secondary sources. Herd effects from the PCV13 pediatric program were considered. Outcomes and costs were evaluated assuming use of PPV23 alone, and alternatively, use of PCV13 → PPV23 among (1) all adults aged ≥ 65 years (n = 5.4 M) and (2) immunocompromised and high-risk adults aged ≥ 65 years (n = 3.0 M). RESULTS: For population no. 1, PCV13 → PPV23 reduced IPD cases by 1100, CAP cases by 7000, and disease costs by $135.8M; vaccination costs increased by $254.3M, and cost per QALY gained was $35,484. For population no. 2, PCV13 → PPV23 reduced IPD cases by 900, CAP cases by 6000, and disease costs by $120.3M; vaccination costs increased by $149.8M, and cost per QALY gained was $10,728. CONCLUSION: Expanding use of PCV13 → PPV23 by funding PCV13 among Canadian adults aged ≥ 65 would be a cost-effective use of healthcare resources. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.17269/s41997-018-0050-9) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6267650 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-62676502018-12-18 Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults Atwood, Mark Beausoleil, Linda Breton, Marie-Claude Laferriere, Craig Sato, Reiko Weycker, Derek Can J Public Health Quantitative Research OBJECTIVES: The Canadian National Advisory Committee on Immunization (NACI) recommends use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in a sequential schedule (PCV13 → PPV23) among adults aged ≥ 65 years and those aged ≥ 18 years who are immunocompromised. In light of recent PCV13 efficacy data from the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA), and new sero-epidemiology data on community-acquired pneumonia (CAP), we examined the economic implications of funding an expanded adult pneumococcal immunization program in Canada. METHODS: A microsimulation model depicting expected lifetime risks, consequences, and costs of invasive pneumococcal disease (IPD) and CAP was developed. PPV23 effectiveness was based on published literature, and PCV13 effectiveness was based on CAPiTA; all other model parameters were based on published data or secondary sources. Herd effects from the PCV13 pediatric program were considered. Outcomes and costs were evaluated assuming use of PPV23 alone, and alternatively, use of PCV13 → PPV23 among (1) all adults aged ≥ 65 years (n = 5.4 M) and (2) immunocompromised and high-risk adults aged ≥ 65 years (n = 3.0 M). RESULTS: For population no. 1, PCV13 → PPV23 reduced IPD cases by 1100, CAP cases by 7000, and disease costs by $135.8M; vaccination costs increased by $254.3M, and cost per QALY gained was $35,484. For population no. 2, PCV13 → PPV23 reduced IPD cases by 900, CAP cases by 6000, and disease costs by $120.3M; vaccination costs increased by $149.8M, and cost per QALY gained was $10,728. CONCLUSION: Expanding use of PCV13 → PPV23 by funding PCV13 among Canadian adults aged ≥ 65 would be a cost-effective use of healthcare resources. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.17269/s41997-018-0050-9) contains supplementary material, which is available to authorized users. Springer International Publishing 2018-05-09 /pmc/articles/PMC6267650/ /pubmed/29981104 http://dx.doi.org/10.17269/s41997-018-0050-9 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Quantitative Research Atwood, Mark Beausoleil, Linda Breton, Marie-Claude Laferriere, Craig Sato, Reiko Weycker, Derek Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults |
title | Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults |
title_full | Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults |
title_fullStr | Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults |
title_full_unstemmed | Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults |
title_short | Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults |
title_sort | cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (pcv13) in canadian adults |
topic | Quantitative Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267650/ https://www.ncbi.nlm.nih.gov/pubmed/29981104 http://dx.doi.org/10.17269/s41997-018-0050-9 |
work_keys_str_mv | AT atwoodmark costeffectivenessofalternativestrategiesforuseof13valentpneumococcalconjugatevaccinepcv13incanadianadults AT beausoleillinda costeffectivenessofalternativestrategiesforuseof13valentpneumococcalconjugatevaccinepcv13incanadianadults AT bretonmarieclaude costeffectivenessofalternativestrategiesforuseof13valentpneumococcalconjugatevaccinepcv13incanadianadults AT laferrierecraig costeffectivenessofalternativestrategiesforuseof13valentpneumococcalconjugatevaccinepcv13incanadianadults AT satoreiko costeffectivenessofalternativestrategiesforuseof13valentpneumococcalconjugatevaccinepcv13incanadianadults AT weyckerderek costeffectivenessofalternativestrategiesforuseof13valentpneumococcalconjugatevaccinepcv13incanadianadults |